The biological functions of vitronectin (Vn) are dependent on its conformation. Whereas plasma Vn is present in a conformation that does not bind to heparin, platelet Vn has been recognized to be in a multimeric, conformationally altered form. To further understand the characteristics of platelet Vn, the molecules present in plasma and total and size-fractionated platelet releasates were compared (1 I immunologically using three conformationally sensitive epitope-defined monoclonal antibodies, (2) functionally for their ability to interact with heparin, and (3) structurally using denaturing and nondenaturing polyacrylamide gel electrophoresis (PAGE). Our data indicate that Vn is present in platelet releasates in two molecular weight (M,) forms. The high M, fractions contain conformationally and structurally ITRONECTIN (Vn), an adhesive glycoprotein present V in the circulation and in a variety of tissues, belongs to a group of adhesion molecules that play key roles in the attachment of cells to their surrounding matrix.'.' In addition to its role as an adhesive glycoprotein, Vn also plays a pivotal regulatory function in the complement, coagulation, and fibrinolytic system. Vn is identical to the S protein of the complement system and thus inhibits complement-mediated cell lysis.3 ' Vn also reduces the rapid inactivation of thrombin and factor Xa by antithrombin I11 in the presence of glycosaminoglycans.6~7 In addition, Vn binds to and stabilizes the biological activity of type 1 plasminogen activator inhibitor (PAI-l), the physiological inhibitor of both tissueand urinary-type plasminogen activator^.'.^ Thus, Vn provides a unique regulatoly link between cell adhesion and proteolytic enzyme cascades.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with I8 U.S.C. section 1734 solely to indicate this fact. bonded complexes of Vn with thrombin-antithrombin I11 and its interaction with either heparin or complement C5b-7 induces conformational changes in the molecule, leading to the exposure of the cryptic heparin binding domain. Conformational changes in the Vn molecule can also be induced by denaturation with chaotropic agents and acidification, and these changes are accompanied by the spontaneous formation of disulfide-linked multimers. '.' The conversion of the native, plasma form of Vn to the conformationally altered, multimeric form has been shown to be critical for its interaction with a number of molecules (ie, interaction with collagen," P-end~rphin,'~ PAI-1,I4 and urokinase receptor"), its ability to bind to cells," and its ability to be incorporated into the extracellular matrix."
A second circulatory pool of Vn is contained within platelets in a rapidly releasable form, which accounts for approximately 0.8% of the circulating pool of Vn.'*.'" Whereas plasma Vn is monomeric and lacks significant exposure of epitopes for conformationally sensitive monoclonal antibodies (MoAbs), Vn present in platelet releasates has been observed to be in a high molecular weight, conformationally altered form.*' Thus, platelets may contain Vn multimers that are already competent for numerous physiological functions. Unfortunately, numerous questions remain concerning the form(s) of Vn in platelets. For example, is the conformation of Vn present in platelet releasates identical to the form derived by the treatment of native Vn with denaturants? Previous studies used only one conformationally sensitive MoAb, but no information is available on the epitope recognized by this MoAb. Moreover, because the exposure of this MoAb's epitope (ie, MoAb 13H1) does not directly correlate with the ability of Vn to bind to heparin-Sepharose," is the cryptic heparin binding site, as well as other cryptic sites, available in the Vn molecule that is present in platelet releasates? We" and others" have developed a series of distinct MoAbs that recognize conformations expressed in denatured Vn. More specifically, epitope mapping of these MoAbs showed that the conformational changes are not limited to the heparin-binding domain, but also occur in the N-terminal somatomedin B domain of Vn (amino acids 1 through 45; MoAb 153) and the connecting regiodfirst hemopexin-like repeat (amino acids 52 through 239; MoAb 1244 and 8E624).
Therefore, we initiated a study to further characterize the conformational, functional, and structural state of Vn present in platelet secretion products in comparison to its form in plasma and the purified form obtained after treatment with denaturants.
A second issue concerns the discrepancies between the detection of PAI-1Nn complexes in platelet releasates and the absence of PAI-1 in fractions containing high molecular weight Vn?' a form that is expected to be competent for complexation with PAI-1 .*' Because the exposure of the MoAb 13H1 epitope does not always correlate with the formation of disulfide-linked Vn multimers?l we extended our study to immunologically, functionally, and structurally analyze the high molecular weight (M,) and low M, forms of Vn in platelet releasates. Finally, do multimers of Vn exist in the platelet a-granules or is platelet activation required for the formation of these multimers analogous to their increase during the preparation of serum? To address this issue, we structurally characterized the form of Vn in a-granules obtained by density gradient cen&ifugation of platelet homogenates.
MATERIALS AND METHODS

Materials.
All chemicals were the highest analytical grade commercially available. Materials were obtained as follows. Column chromatography supplies were from Pharmacia Fine Chemicals (Piscataway, NJ). Calcium ionophore A23187, prostaglandin El, and human thrombin were from Sigma (St Louis, MO). Peroxidaselabeled secondary antibodies and ECL Western blotting detection system were from Amersham (Arlington Heights, IL). Nitrocellulose sheets were from Schleicher and Schuell (Keene, NH). Biotin-labeled secondary antibodies, streptavidin-alkaline phosphatase complex, and p-nitrophenyl phosphate (pNPP) were from Zymed (South San Francisco, CA). Reagents for polyacrylamide gel electrophoresis (PAGE) were from Bio-Rad (Richmond, CA).
Human Vn was purified by heparin affinity chromatography in the presence of 8 m o m urea.z6 This form of Vn was designated as denatured Vn. PAI-I was isolated from Escherichia coli strain JM 105, containing the PAI-I expression plasmid pMBL 11 (kindly provided by D r H. Pannekoek, University of Amsterdam, Amsterdam, The nether land^)'^ as described.zz Antisera to Vn and PAI-I were raised in New Zealand White rabbits using standard procedures.28 MoAb 153 (directed against amino acid [aa] 1 through 40) and MoAb 1244 (directed against aa 52 through 239) were obtained by standard hybridoma techniques using denatured Vn as immunogen.2z The hybridoma clone producing MoAb 8E6 (directed against aa 52 through 239 of Vnm) was kindly provided by Dr D. Mosher (University of Wisconsin, Madison, WI). MoAbs were produced in mice as ascites fluid, and the resulting IgG was purified by using protein A-agarose (MoAbs 153 and 1244) or used without further fractionation (MoAb 8E6).
Preparation of washed human platelets and platelet releasates. Venous blood from healthy volunteers was collected into 10 mL acid-citrate-dextrose anticoagulant containing 85 mmol/L sodium acetate, 65 mmoVL citric acid, 2% D-glucose, pH 4.5, to a final volume of 60 mL. Platelet-rich plasma was prepared by centrifugation (270g for 15 minutes). Prostaglandin El (PGE,; l ,umoVL) and EDTA (1 mom) were added to the platelet-rich plasma. The platelets were sedimented by centrifugation at 9OOg for 10 minutes, the resulting platelet-poor plasma (PPP) was harvested, and the pellet was resuspended and washed two times in platelet wash buffer (10
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mmol/L HEPES, 137 mmoVL NaCI, 4 mmoVL KCI, 1 mmom MgCI2, 0.1% D-glucose, pH 6.8) containing 0.1% bovine serum albumin and 0.5 mmoVL EDTA and one time in platelet wash buffer containing 0.5 mmoVL EDTA. Finally, the platelets were resuspended in platelet wash buffer (5 x 109/mL). Platelet releasates were obtained by treating the washed platelet suspension with either thrombin (1 NIH U/mL) or calcium ionophore A23187 (1 @mom) and incubating at room temperature for 10 minutes. The platelet suspension was mixed every 2 minutes by end-over-end rotation. Finally, the platelet suspension and the PPP (in 1 mmol/L EDTA, 1 pmoVL PGE,) were centrifuged at 10,OOOg for 2 minutes and the supernatants were collected by gentle aspiration and either analyzed immediately or frozen at -80°C until assayed. Platelets were diluted in homogenization buffer (108 mmoVL NaCI, 38 mmoV L KCI, 1.7 mmol/L NaHC03, 21.2 mmoVL Na-citrate, 27.8 mmol/ L D-glucose, 1.1 mmol/L MgCI2, and 1 mmoVL theophylline, pH 6.5) to a final concentration of 1 X 109/mL and sonicated using an Astrason Ultrasonic processor XL (Heat Systems Inc, Farmingdale, NY) five times (at 4"C, with 3 seconds of sonication on setting 2 followed by a 15-second pause between each sonication). Residual intact platelets were removed by centrifugation (15 minutes at 2,OOOg at 22°C). The membrane/organelle/cytosol-containing supernatants were pooled and centrifuged (16,OOOg for 15 minutes at 4°C). and the membrane/organelle-rich pellet was resuspended in 5 mL of homogenization buffer. Two consecutive centrifugation protocols were used to separate a-granules from other platelet organelles. First, a metrizamide gradientz9 was used to deplete the platelet homogenate of dense granules. For this purpose, membrane/organelle-rich platelet homogenates were mixed 1:l with a 40% metrizamide solution (Accurate Chemical and Scientific Co, Westbury, NY) and this mixture was layered on top of a two-step gradient consisting of 1 mL of 35% metrizamide underlayered with 0.5 mL of 38% metrizamide. After centrifugation (1 hour at 4°C at 100,OOOg; VTi-65 rotor: Beckman L7-65 ultracentrifuge; Beckman Instruments, Inc, Palo Alto, CA), dense granules were located in a compact pellet at the bottom of the centrifuge tube, whereas the a-granules were present in a thick band at the interface above the 35% metrizamide solution. Density gradient fractionation on isotonic Percoll gradients" was subsequently used as the second step to separate a-granules from other platelet organelles. This procedure entailed mixing the samples 1:l with 90% stock isotonic Percoll (1 mL of 1.5 m o m NaCl + 9 mL of Percoll; Pharmacia LKB Biotechnology, Inc, Piscataway, NJ) and subjecting this mixture to ultracentrifugation (4°C for 30 minutes at 20,OOOg). The a-granules were recovered as an opaque band at a density of 1.06 to 1.1 g/L and were washed twice using an airfuge (100,000g for 15 minutes at 22'C). Control experiments using platelets incubated with 3H-serotinin (Du Pont Co, Wilmington, DE) and subcellular fractionation, as described above, followed by analysis of the radioactivity in the various fractions using a Beckman LS3801 Scintillation Counter showed that this two-step gradient procedure (>98%) depleted a-granule-containing fractions of 'H-serotinin. Conformational changes in the Vn molecule were quantified by competitive ELISA as d e s~r i b e d .~~,~~ Briefly, microtiter wells were coated with denatured Vn (1 pg/mL in PBS at 4°C for 16 hours), and nonspecific binding sites on the plastic dishes were blocked by incubating the washed wells for 1 hour at 37°C in PBS containing 3% casein and 0.05% Tween 20. The wells were coincubated for 1 hour with a constant amount of anti-Vn IgG (50 ng/mL; MoAbs 153 and 1244) or ascites (1/50,000 dilution; clone 8E6) and the indicated concentration of Vn-containing samples in PBS containing 0.1 % casein and 0.1% Tween 20. Bound IgG was detected with biotinconjugated goat antimouse IgG, followed by streptavidin alkaline phosphatase conjugate and the chromogenic substrate pNPP. The Platelet homogenization and isolation of a-granules.
Competitive enzyme-linked immunosorbent assay (ELISA).
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From change of absorbance at 405 nm of duplicate wells was determined and the absorbance of wells not incubated with primary antibodies but otherwise treated identically was subtracted. Results were expressed as the percentage binding in the absence of soluble competitor. The data presented in the result section are representative for three independent experiments performed with blood obtained from different donors.
The binding of Vn to glycosaminoglycans was tested by heparin affinity chromatography. Unspecific protein binding sites on the heparin Sepharose or unconjugated Sepharose 4B beads were blocked by incubation with PBS containing 3% casein and 0.05% Tween 20. Afterwards, the beads were washed with PBS containing 0.05% Tween 20 (PBSRween). Vn containing samples were batch-absorbed for 3 hours at room temperature, and the beads were sedimentated by centrifugation. The beads were washed with 10-bead volumes of PBSRween and eluted with PBSmween containing 2 moVL NaCI. The starting materials, the nonbound fractions, and the eluted fractions were analyzed by sodium dodecyl sulfate-PAGE (SDS-PAGE) followed by immunoblotting using MoAb 1244 (see below). Further elution attempts by boiling of the beads in SDS-containing sample buffer showed that Vn was completely eluted with 2 m o l n NaCl (data not shown).
SDS-PAGE was performed in slab gels according to Laemmli." The upper stacking gel contained 4% acrylamide, whereas the lower resolving gel contained 9% acrylamide. Reduction of sample was performed by the addition of dithiothreitol (50 mmoln) to the sample buffer. Native PAGE was performed on 3% acrylamide (stacking gel) and 7.5% acrylamide (resolving gel) in the absence of SDS using the Laemmli buffer system as described." After electrophoresis, the proteins in the gel were transferred onto nitrocellulose membranes and analyzed by immunoblotting, as described."
Protein concentrations were determined by the bicinchoninic acid method (Pierce, Rockford, IL). The Vn concentrations in biological samples were estimated by quantitative immunoblotting (MoAb 1244) of reduced SDS-PAGE using serial dilutions (4 dilution each) of platelet-poor plasma, supematant of stimulated platelets. and purified Vn standards. The dilutions were chosen to be in the linear range of the immunoblotting system. This procedure was found to be more accurate than conventional E L S A methods due to the sensitivity of the antibodies to the conformation of Vn'" (data not shown).
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RESULTS
Immunological analysis of platelet-derived Vn. The expression of conformationally sensitive epitopes in the Vn molecules in blood was compared by competitive immunoassays using the supematant of stimulated platelets and plasma derived from the same donor (Fig 1) . The Vn concentration in each sample was determined by quantitative immunoblotting (see the Materials and Methods). Vn present in the supematant of stimulated platelets reacted at least IO-fold better than did plasma Vn with MoAb 153 (epitope located between aa I and 40) and MoAb 1244 (epitope located between aa 52 and 239; Fig l A and B) . In comparison, purified denatured Vn was a significantly more potent competitor than the forms of Vn derived from platelets for either the 153 or 1244 antibody in this assay (Fig IA and B , respectively). These data extend the observation of Stockmann et al" using MoAb 13H1 to two additional conformationsensitive MoAbs with defined epitopes, showing that platelet-derived Vn expresses epitopes not present in the plasma Vn but present in the denatured molecule. However, analysis nitrocellulose membranes after SDS-PAGE (Fig 1 C, insert) , indicating that the failure to compete with MoAb 8E6 was not due to a general lack of the 8E6 epitope in either platelet or plasma Vn. These results suggest that the platelet Vn is in a conformation distinct from either the Vn in plasma or the form expressed by the denatured molecule. Functional analysis of the binding of platelet-derived Vn to heparin. Although only 2% of Vn in plasma binds to heparin-Sepharose, the relative amount increases to approximately 7% by the generation of serum." One possibility is that platelet Vn, at least in part, accounts for the relative increase in heparin binding. To investigate this possibility, the expression of the heparin binding domain was compared between platelet and plasma Vn. Figure 2 indicates that a significant portion of the platelet Vn bound to heparin-Sepharose and could be eluted from this molecule by an increase in the ionic strength. In comparison, no binding of plasma Vn was detected under these conditions (Fig 2, lanes 5  through 8) . In control experiments, neither platelet nor plasma Vn bound to unconjugated Sepharose beads (data not shown), indicating that the binding of platelet-derived Vn was specific for heparin.
Experimentally, conformational changes of the Vn molecule are closely linked to the formation of noncovalent and covalent (ie, disulfide-linked) multimers.'.* To determine whether these in vitro findings can be extended to the form secreted from platelets, the electrophoretic mobility of Vn present in the supematant of either thrombin or calcium-ionophore stimulated platelets was compared with the form present in plasma from the same donor (Fig 3) . Under reducing conditions, it is known that plasma Vn migrates as a doublet of M, 75,000 and 65,000 (Fig 3A, lane 1) . In comparison to plasma Vn, the relative intensity of the M, 65,000 band was increased in platelet releasates (Fig 3A, lanes 3 and 4; compare with Fig 3A, lane l) , consistent with previous observations.*" The Structural analysis of platelet-derived Vn. supernatant of nonstimulated platelets was practically devoid of Vn immunoreactivity (Fig 3A through C, lanes 2) . Analysis of the samples under nonreducing conditions showed that plasma Vn could be detected as a single, broad immunological reactive band between M, 75,000 and 65,000 (Fig 3B,  lane I) , whereas the supernatant of stimulated platelets contained two major bands, ie, the M, 75,000 to 65,000 broad band and a high molecular weight form (2200 kD; Fig 3B,  lanes 3 and 4) . In contrast, denatured Vn could be detected as disulfide-linked multimers in the stacking gel and little Vn immunoreactivity was present in the separating gel ( Fig  3B, lane 5) . The latter results suggest that the M, of the Vn multimers associated with denatured Vn exceed the M, of Vn derived from either thrombin-or calcium ionophorestimulated platelets. Electrophoresis under nondenaturing conditions was used to begin to understand the contribution of noncovalent interactions stabilizing Vn multimers released by platelets (Fig 3C) . Again, the majority of denatured Vn was retained in the stacking gel (Fig 3C, lane 5) , whereas plasma Vn could be immunologically detected as a broad band that migrated to the anode (Fig 3C, lane I) . In contrast, platelet Vn (Fig 3C, lanes 3 and 4) migrated as a heterogenous band with a mobility in between denatured (lane 5) and plasma Vn (lane 1). Similar results were obtained using rabbit antihuman Vn IgG as the detecting antibody in immunoblots (data not shown).
Structural, immunological, and functional analysis of the two distinct Vn populations secreted from platelets. Recent studies indicated that Vn in platelet releasates could be separated into a high M, form and a low M, form by chromatography on a molecular sieving column." To further define the Vn molecules in platelets, fresh platelet releasates were chromatographed on a Sepharyl S-300 column (Fig 4) , and then these populations of Vn were characterized separately immunologically, functionally, and structurally. Figure 4A 3) and low M, pools (lanes 4 through 6) . and, after washing, the beads were eluted with 2 mollL NaCl and analyzed for Vn antigen as described in the legend to Fig 2. Lanes 1 and 4 , starting material; lanes 2 and 5, flow-through; and lanes 3 and 6, elution. The mobility of M. standards is indicated.
4A, insert). In contrast, plasma Vn eluted as a single peak close to the position of albumin (data not shown). The electrophoretic mobility of both Vn pools was analyzed by SDS-PAGE under nonreducing conditions (Fig 4B) . Whereas the starting material (Fig 4A, lane 1) contained both monomeric Vn and disulfide-linked multimers, covalently stabilized multimers were exclusively present in the high M, peak (lane 2). In contrast, the low M, pool contained monomeric or SDS-unstable Vn multimers (lane 3).
The expression of conformationally sensitive epitopes was compared between the low and high M, pools derived from the gel filtration studies (Fig 5A) . Vn present in the high M, pool competed with the binding of MoAbs 153 and 1244 to immobilized Vn in a dose-dependent manner; the competition was significantly less in the low M, pool. Thus, the conformationally altered Vn was mostly contained in the high M, pool. The high and low M, forms of platelet-derived Vn were analyzed for their ability to bind to heparin ( Fig  5B) . Although the Vn contained in the low M, pool failed to bind to heparin (lane 6), Vn multimers present in the high M, pool bound to and were specifically eluted from the heparin beads (lane 3). These data indicate that Vn is released from platelets in two structurally and functionally distinct pools.
Evidence for the storage of disuljide-linked Vn multimers within platelet a-granules. Preissner et alZ0 reported that multimers and monomers of Vn were present in the releasates of platelets. Our present data extend these observations by showing that the released high M, multimers of Vn are both conformationally and functionally (ie, glycosaminoglycan binding) distinct from the released lower M, form. To understand whether platelet activation was required for the induction of Vn multimerization, lysates of nonreleased platelets were prepared and analyzed by SDS-PAGE under nonreducing conditions. Vn present in platelet lysates migrated as a doublet of M, 75 and 65 kD, and no disulfidelinked Vn multimers were detectable (data not shown). Because it is known that the cytoplasm of cells contain agents capable of reducing disulfide bonds,g3 we investigated the possibility of separating the platelet storage granules from the platelet cytosol and then analyzing the status of Vn present within these isolated organelles.
Previous studies based on the simultaneous release of Vn with a-granule marker proteins (ie, platelet factor 4?') together with immunoelectron microscopic localization studies.I4 strongly suggested that platelet Vn is present within agranules. Density gradient fractionation was used to isolate these granules from other organelles and define the structural status of this stored Vn. To isolate platelet a-granules, platelets were sonicated and initially fractionated on metrizamide gradients to obtain a membrane/organelle fraction that was depleted of platelet cytosol and platelet dense granules." This preparation was further subfractionated on a 45% Percoll gradient to separate low-density membrane-rich fractions and high-density a-granules containing fractions." The resulting fractions were simultaneously analyzed by immunoblotting for Vn and PAI-1. Both proteins codistributed in the gradient and were detected in a low-density membrane fraction and a high-density a-granule-rich fraction (Fig 6A) . It should be noted that the codistribution of PAI-I and Vn does not show that Vn within a-granules is complexed with PAI-1. Indeed, previous studies provided evidence that PAI-1 N n complexes are formed in the releasates after stimulation of platelets with physiological agonists.?' The structural integrity of the resulting a-granules was confirmed by transmission electron microscopy." The low-density membrane fraction and the high-density a-granule fraction were analyzed by SDS-PAGE under nonreducing conditions, followed by immunoblotting (Fig 6B) . Vn associated with the membrane fraction (lane 1) or the a-granule fraction (lane 2) was present in high M, disulfide-linked multimers and monomers. As a control, the mobility of monomeric plasma Vn (lane 3) was shown not to be affected by dilutions into the Percollhuffer conditions used for the isolation of the a- granules (lane 4). Thus, platelet a-granules contain disulfidelinked Vn multimers, suggesting that platelet activation is apparently not required for the generation of multimeric, conformationally and functionally altered Vn.
DISCUSSION
In the present study, we provided evidence that the blood circulation contains two structurally and, more importantly, functionally distinct pools of Vn. This conclusion is based on the comparison of platelet and plasma Vn by gel electrophoresis, gel filtration, competitive ELISAs using a panel of conformationally sensitive antibodies, and heparin affinity chromatography. Although plasma Vn is present in the monomeric, native conformation, a significant portion of the Vn released from stimulated platelets is present in a multimeric, conformationally altered form, and this form binds to glycosaminoglycans.
Our gel filtration studies of freshly prepared platelet releasates also showed that PAL1 and Vn codistributed in high M, fractions, whereas the lower M, forms of Vn and PAI-I eluted separately (Fig 4) . Published quantitative studies have indicated that platelets contain approximately 65,000 Vn molecules per platelet,'" whereas the number of PAI-I molecules per platelet was estimated to be 4,000 to 8,000.'" Although these observations indicate that platelet a-granules contain an eightfold to 16-fold molar excess of Vn versus PAL I, the detection of free PAI-1 within the lower molecular weight containing column fractions is also consistent with its packaging and its activity state within a-granules. More specifically, recent data from our group have shown that Vn and PAI-I are not packaged together within the a-granules, thus enabling PAI-I released from the a-granules to interact and form complexes with molecules such as proteoglycans, fibrin, and Vn present in a number of different sites, including extracellular matrices, cell surfaces, or within platelet releasates.'s These data are also consistent with the observation of Eitzman et al,." who showed that Vn protects PAI-I from inactivation by a 14-amino acid PAI-I peptide corresponding to the PAI-I reactive center loop in a purified system, whereas if platelets were used as the source of PAI-1 and Vn, the peptide was able to gain access to PAI-I, and this inhibitor was not protected from inactivation. Moreover, the majority of platelet PAI-I is present in the latent form?' and this form of the inhibitor fails to bind to Vn with high affinity.'" Previous studies indicated that multimeric, high M, forms of Vn have increased affinity for PAI-I in comparison to monomeric Vn.I4 Thus, under conditions in which active PAI-I is the limiting factor, PAI-I is expected to preferentially interact with the high M, Vn forms, and this assumption was confirmed in the gel filtration experiments (Fig 4) . The conclusion that only a portion of this high M, form of Vn was complexed with PAL1 was also supported by our analysis using conformationally sensitive antibodies.
Whereas the expression of the MoAb 1244 epitope in Vn is
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From not affected by PAI-1, the MoAb 153 used to determine conformational changes in the N-terminal somatomedin B domain of Vn is able to block the binding of PAI-1 to Vn in a dose-dependent manner and does not detect Vn in complex with PAI-1." Accordingly, complex formation of PAI-1 with Vn in the supernatant of stimulated platelets actually reduces the extent of immunoepitopes detectable by MoAb 153, leading to an underestimation of the extent of the conformational changes within the Vn molecule. In light of this situation, the fact that conformational changes were detected by MoAb 153 indicates that conformationally altered Vn is present in the supernatant of stimulated platelets in a form not complexed with PAI-1.
A number of considerations suggest that platelet Vn is conformationally and structurally different from denatured Vn purified from serum in the presence of urea and reducing agents? Firstly, the majority of platelet Vn entered the separating gel upon fractionation by nonreducing SDS-PAGE and native PAGE, whereas denatured Vn was retained in the stacking gel. Secondly, the size of denatured Vn was reported to exceed lo6 daltons,26 and chromatography on Sephacryl S-300 resulted in its elution in the void volume (ie, >2 X lo6; data not shown), in contrast to platelet Vn that eluted close to but distinct from the void volume of this gel filtration column (Fig 4) . Thus, based on electrophoretic mobility and gel filtration studies, platelet Vn is present in lower molecular weight oligomers. Thirdly, the expression of conformationally sensitive epitopes (ie, MoAbs 153 and 1244) was more pronounced in denatured Vn in comparison to plateletderived Vn. Fourthly, the MoAb 8E6 epitope was not expressed in platelet Vn, but strongly in denatured Vn. Taken together, these results suggest that platelets contain a population of Vn that is unique with respect to the conformational state and degree of multimerization.
Although our studies indicated that multimeric Vn can be readily detected in platelet releasates, analysis of Vn in platelet lysates by nonreducing SDS-PAGE followed by immunoblotting showed only a doublet of M, 75,000 and 65,000 (data not shown), which is in accord with the data of Asch and Podack.40 Because it is known that cytoplasm of cells contains agents capable of reducing disulfide bonds,33 a series of subcellular fractionation experiments were used to address the issue of whether platelet activation is required for the formation of disulfide-linked Vn multimers. Our combined biochemical and immunologic studies confirm and extend previous immunoelectron microscopic and functional indicating that Vn is a constituent of a-granules. Furthermore, our ability to detect disulfide-linked Vn multimers in fractions containing morphologically intact agranules suggests that the platelet release reaction is not required for the formation of Vn multimers. Further studies will be required to determine if the high M, conformationally and functionally altered form of Vn within platelets is derived by differential processing of Vn during megakaryocytopoiesis or by platelet uptake and processing of native Vnt trace multimeric Vn from the plasma compartment. The ability of platelets to adhere during thrombosis and increase their local concentration up to 200-fold as compared with the circulating level4' suggests that this multimeric form of Vn will be released at the platelet-platelet, platelet-cell, or platelet-matrix interface, thereby expressing a functional repertoire distinct from the form in plasma.
